Vidarabine is an antiviral drug which is active against herpes simplex and varicella zoster viruses. The drug was originally intended as an anti-cancer drug. The anti-viral activity of vidarabine was first described by M. Privat de Garilhe and J. De Rudder in 1964. It was the first nucleoside analog antiviral to be given systemically and was the first agent to be licensed for the treatment of systematic herpes virus infection in humans. It was University of Alabama at Birmingham researcher and physician Dr. Richard Whitley in 1976 where the clinical effectiveness of vidarabine was first realized, and vidarabine was used in the treatment of many viral diseases.
Properties:
Appearance & Physical State: White to off-white crystalline powder.
Density: 2.08g/cm3
Melting Point: 260-265ºC (dec.)
Boiling Point: 676.3ºC at 760mmHg
Flash Point: 362.8ºC
Refractive Index: 1.907
Related Prodcuts:
Flupirtine maleate; Halofuginone hydrobromide; Rifampicin; Rifaximin; Rifapentine; Streptozocin; Tegafur